Currently, Michael Merges is Director of Catalent’s Biopharmaceutical Support Services, focusing on the transfer, development, validation, and performance of bioassays, immunoassays, microbiological assays, and viral clearance assays. Mr. Merges has experience with many techniques, including cell-based (primary cells and cell lines) bioassays, immunological/neutralization assays, ELISA, and Flow Cytometry. He recently joined Catalent from Lonza where he was Associate Director of Lonza’s Bioservices. Prior to that he was at the University of Maryland’s Institute of Human Virology where he served as the Institute’s Research Supervisor. He has also conducted viral immunology research at the National Cancer Institute and Johns Hopkins University. He obtained his Bachelors Degree in Microbiology from The Pennsylvania State University and his Masters Degree in Microbiology/Virology from Hood College.
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,200 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
Media Contact: Patricia McGee
T 1+(732) 537 6407
patricia.mcgee@catalent.com
